Toxic Protein Hijacks Norepinephrine to Drive Alzheimer's Disease (2 of 2) (VIDEO)
Caption
To date, there is no treatment to cure Alzheimer's disease (AD). We discovered noradrenaline as a key missing piece of the Alzheimer's puzzle linking amyloid and tau, the two hallmarks of AD. Noradrenaline and amyloid together act through the α2 adrenaline receptor to induce abnormal tau. Repurposing clinically tested α2 blockers could provide potential immediate treatment for AD. This material relates to a paper that appeared in the Jan. 15, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by F. Zhang at University of Alabama at Birmingham in Birmingham, AL; and colleagues was titled, "Amyloid β redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade."
Credit
Qin Wang, University of Alabama at Birmingham
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.
License
Licensed content